论文部分内容阅读
目的探讨坎地沙坦酯对原发性高血压患者的血压及尿微量白蛋白的影响。方法80例原发性高血压伴尿微量白蛋白患者随机分为两组:坎地沙坦组40例,口服坎地沙坦酯8～16mg/d;卡托普利组40例口服卡托普利37.5～150mg/d,疗程12周。分别测量两组治疗前后血压、尿微量白蛋白(ALB)、血肌酐(Scr)、尿肌酐并计算内生肌酐清除率(Ccr)。结果两组治疗后血压及尿微量白蛋白均显著下降(P<0.01),组间比较差异有统计学意义(P>0.05);两组治疗前后血肌酐、内生肌酐清除率均无明显变化(P>0.05)。卡托普利组咳嗽发生率27.5%,其中有6例不能耐受咳嗽而退出试验,坎地沙坦组无咳嗽病例发生。结论坎地沙坦酯不仅能有效降低血压,而且能降低尿微量白蛋白,与卡托普利疗效相似。
Objective To investigate the effect of candesartan cilexetil on blood pressure and urinary albumin in patients with essential hypertension. Methods Eighty patients with essential hypertension and microalbuminuria were randomly divided into two groups: candesartan group 40 cases, candesartan cilexetil 8-16 mg / d, captopril group 40 cases were given Cato Puli 37.5 ~ 150mg / d, treatment for 12 weeks. Blood pressure, urinary albumin (ALB), serum creatinine (Scr) and urinary creatinine were measured before and after treatment. Endogenous creatinine clearance (Ccr) was calculated. Results After treatment, blood pressure and urinary albumin were significantly decreased in both groups (P <0.01), with significant difference between the two groups (P> 0.05). There was no significant difference in serum creatinine and endogenous creatinine clearance between the two groups before and after treatment (P> 0.05). Captopril group, the incidence of cough 27.5%, of which 6 patients can not tolerate cough and exit the test, no cases of candesartan cough occurred. Conclusion Candesartan cilexetil not only can effectively reduce blood pressure, but also reduce urinary microalbumin, and captopril similar efficacy.